# A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

> **NCT01899053** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Advanced Nonhematologic Malignancies

## Interventions

- **DRUG:** TAK-228
- **DRUG:** TAK-117

## Key facts

- **NCT ID:** NCT01899053
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-28
- **Primary completion:** 2017-01-31
- **Final completion:** 2018-04-30
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01899053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01899053, "A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01899053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*